Companies Danaher Corp /DE/
Danaher Corp /DE/ (DHR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Danaher Corp /DE/’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers50th pct.Of 14 peer CEOs
CEO pay, last three years
- $20,903,282FY2023
- $22,107,164FY2024
- $23,795,280FY2025
CEO total pay was $23,795,280 in fiscal 2025, up from $22,107,164 in fiscal 2024.
FY2025: salary $1,400,000 · bonus $0 · stock awards $9,292,370 · option awards $8,386,657
Executives and directors
Rainer Blair · CEOJose-Carlos Gutierrez-Ramos · EVPJulie Montgomery · EVPChristopher Riley · EVPMatthew McGrew · CFOA. Shane Sanders · Independent DirectorAlan G. Spoon · Independent DirectorCharles W. Lamanna · Independent DirectorElias A. Zerhouni, MD · Independent DirectorFeroz Dewan · Independent DirectorJessica L. Mega, MD, MPH · Former director (through FY2025)John T. Schwieters · Independent DirectorLinda Filler · Lead Independent DirectorMitchell P. Rales · DirectorRaymond C. Stevens, Ph.D · Independent DirectorSteven M. Rales · Chair of the BoardTeri L. List · Independent Director
Frequently asked questions
Who was the highest-paid executive at Danaher Corp /DE/ in fiscal 2025?
As disclosed, Rainer Blair (President and CEO) was the highest-paid executive at Danaher Corp /DE/ in fiscal 2025, with total compensation of $23,795,280.
How does Danaher Corp /DE/'s chief executive pay compare to its disclosed peer group?
As disclosed, Rainer Blair's total compensation ranked at the 50th percentile of Danaher Corp /DE/'s disclosed peer group.
What is Danaher Corp /DE/'s CEO-to-median employee pay ratio?
As disclosed, Danaher Corp /DE/'s CEO-to-median employee pay ratio was 343:1.
How did shareholders vote on Danaher Corp /DE/'s executive compensation?
As disclosed, 93.02% of shareholders supported Danaher Corp /DE/'s executive compensation in the latest say-on-pay vote.
How much does Danaher Corp /DE/ spend in total on board compensation for fiscal 2025?
As disclosed, Danaher Corp /DE/ reported total board compensation of $2,545,122 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Rainer Blair | $1,400,000 | $0 | $9,292,370 | $8,386,657 | $4,194,400 | $0 | $521,853 | $23,795,280 |
| President and CEO | ||||||||
| Julie Montgomery | 848,000 | 0 | 4,425,309 | 4,294,467 | 1,587,880 | 0 | 139,623 | 11,295,279 |
| Executive Vice President | ||||||||
| Christopher Riley | 848,000 | 0 | 4,425,309 | 4,294,467 | 1,587,880 | 0 | 100,192 | 11,255,848 |
| Executive Vice President | ||||||||
| Matthew McGrew | 1,005,330 | 0 | 2,519,058 | 2,273,537 | 1,882,480 | 0 | 287,114 | 7,967,519 |
| Executive Vice President and CFO | ||||||||
| Jose-Carlos Gutierrez-Ramos | 888,460 | 0 | 1,959,422 | 1,768,323 | 1,530,550 | 0 | 97,016 | 6,243,771 |
| Executive Vice President | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Rainer Blair | $23,795,280 | $22,107,164 | $20,903,282 | ↑ +1,688,116 |
| Julie Montgomery | 11,295,279 | — | — | — |
| Christopher Riley | 11,255,848 | — | — | — |
| Matthew McGrew | 7,967,519 | 7,467,394 | 7,496,078 | ↑ +500,125 |
| Jose-Carlos Gutierrez-Ramos | 6,243,771 | 7,499,419 | 7,197,185 | ↓ −1,255,648 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Compensation should fairly pay directors for work required in a company of our size and scope, and differentiate among directors where appropriate to reflect different levels of responsibilities; a significant portion should be stock-based to align with long-term shareholder interests.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Rainer Blair | PSU | 2025-03-01 | 9,988 | 39,950 | — | 79,900 | $9,292,370 |
| Jose-Carlos Gutierrez-Ramos | PSU | 2025-03-01 | 2,106 | 8,424 | — | 16,848 | 1,959,422 |
| Christopher Riley | PSU | 2025-03-01 | — | 12,034 | — | — | 2,465,887 |
| Matthew McGrew | OPTION | 2025-03-01 | — | — | 30,943 | — | 2,273,537 |
| Matthew McGrew | PSU | 2025-03-01 | 2,708 | 10,830 | — | 21,660 | 2,519,058 |
| Jose-Carlos Gutierrez-Ramos | OPTION | 2025-03-01 | — | — | 24,067 | — | 1,768,323 |
| Julie Montgomery | OPTION | 2025-03-01 | — | — | 34,381 | — | 2,526,144 |
| Christopher Riley | OPTION | 2025-03-01 | — | — | 34,381 | — | 2,526,144 |
| Julie Montgomery | OPTION | 2025-03-01 | — | — | 24,067 | — | 1,768,323 |
| Christopher Riley | OPTION | 2025-03-01 | — | — | 24,067 | — | 1,768,323 |
| Rainer Blair | OPTION | 2025-03-01 | — | — | 114,143 | — | 8,386,657 |
| Christopher Riley | PSU | 2025-03-01 | 2,106 | 8,424 | — | 16,848 | 1,959,422 |
| Julie Montgomery | PSU | 2025-03-01 | 2,106 | 8,424 | — | 16,848 | 1,959,422 |
| Julie Montgomery | PSU | 2025-03-01 | — | 12,034 | — | — | 2,465,887 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Rainer Blair | $0 | $9,292,370 | $8,386,657 | 52.6% |
| Jose-Carlos Gutierrez-Ramos | 0 | 1,959,422 | 1,768,323 | 52.6% |
| Christopher Riley | 0 | 4,425,309 | 4,294,467 | 50.8% |
| Matthew McGrew | 0 | 2,519,058 | 2,273,537 | 52.6% |
| Julie Montgomery | 0 | 4,425,309 | 4,294,467 | 50.8% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Julie Montgomery | RSU | 478 | — | $109,653 |
| Julie Montgomery | RSU | 519 | — | 119,267 |
| Julie Montgomery | RSU | 733 | — | 169,528 |
| Christopher Riley | RSU | 778 | — | 178,100 |
| Julie Montgomery | RSU | 848 | — | 196,900 |
| Christopher Riley | RSU | 1,046 | — | 242,901 |
| Christopher Riley | RSU | 1,222 | — | 282,509 |
| Julie Montgomery | Option | 1,272 | 240.13 | — |
| Julie Montgomery | Option | 1,482 | 241.22 | — |
| Julie Montgomery | Option | 1,486 | 198.09 | — |
| Jose-Carlos Gutierrez-Ramos | RSU | 1,695 | — | 393,799 |
| Jose-Carlos Gutierrez-Ramos | RSU | 1,710 | — | 395,489 |
| Jose-Carlos Gutierrez-Ramos | RSU | 2,199 | — | 503,395 |
| Matthew McGrew | RSU | 2,199 | — | 508,469 |
| Christopher Riley | Option | 2,221 | 241.22 | — |
| Jose-Carlos Gutierrez-Ramos | RSU | 2,260 | — | 517,588 |
| Christopher Riley | Option | 2,517 | 241.22 | — |
| Matthew McGrew | RSU | 2,684 | — | 623,458 |
| Christopher Riley | Option | 3,715 | 198.09 | — |
| Julie Montgomery | Option | 4,582 | 221.29 | — |
| Jose-Carlos Gutierrez-Ramos | Option | 4,951 | 198.09 | — |
| Julie Montgomery | Option | 5,235 | 255.87 | — |
| Jose-Carlos Gutierrez-Ramos | Option | 5,235 | 255.87 | — |
| Christopher Riley | Option | 5,650 | 221.29 | — |
| Jose-Carlos Gutierrez-Ramos | Option | 6,107 | 221.29 | — |
| Jose-Carlos Gutierrez-Ramos | Option | 7,107 | 241.22 | — |
| Rainer Blair | RSU | 7,817 | — | 1,807,800 |
| Rainer Blair | RSU | 8,474 | — | 1,968,590 |
| Christopher Riley | Option | 11,632 | 255.87 | — |
| Christopher Riley | RSU | 12,034 | — | 2,754,823 |
| Julie Montgomery | RSU | 12,034 | — | 2,754,823 |
| Matthew McGrew | Option | 12,585 | 241.22 | — |
| Matthew McGrew | Option | 13,920 | 198.09 | — |
| Jose-Carlos Gutierrez-Ramos | Option | 16,285 | 255.87 | — |
| Christopher Riley | RSU | 16,848 | — | 3,878,410 |
| Julie Montgomery | RSU | 16,848 | — | 3,878,410 |
| Jose-Carlos Gutierrez-Ramos | RSU | 16,848 | — | 3,878,410 |
| Jose-Carlos Gutierrez-Ramos | Option | 18,320 | 221.29 | — |
| Rainer Blair | RSU | 19,900 | — | 18,392,980 |
| Matthew McGrew | Option | 20,937 | 255.87 | — |
| Matthew McGrew | RSU | 21,660 | — | 4,986,132 |
| Christopher Riley | Option | 24,067 | 207.76 | — |
| Julie Montgomery | Option | 24,067 | 207.76 | — |
| Matthew McGrew | Option | 29,007 | 221.29 | — |
| Matthew McGrew | Option | 30,943 | 207.76 | — |
| Christopher Riley | Option | 34,381 | 207.76 | — |
| Rainer Blair | Option | 41,457 | 241.22 | — |
| Rainer Blair | Option | 46,405 | 198.09 | — |
| Rainer Blair | Option | 74,443 | 255.87 | — |
| Rainer Blair | Option | 91,602 | 221.29 | — |
| Rainer Blair | Option | 114,143 | 207.76 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Linda FillerIndependent · Lead Independent Director · Nominating & Governance (Chair) · Science & Technology | $192,500 | $110,178 | $110,856 | $0 | $0 | $413,534 |
| Teri L. ListIndependent · Audit · Compensation (Chair) | 158,500 | 110,178 | 110,856 | 0 | 0 | 379,534 |
| A. Shane SandersIndependent · Audit (Chair) · Nominating & Governance | — | 267,678 | 110,856 | 0 | 0 | 378,534 |
| Charles W. LamannaIndependent · Science & Technology · Newly elected | 111,150 | 131,370 | 132,164 | 0 | 0 | 374,684 |
| Elias A. Zerhouni, MDIndependent · Nominating & Governance · Science & Technology (Chair) | — | 262,678 | 110,856 | 0 | 0 | 373,534 |
| Raymond C. Stevens, Ph.DIndependent · Audit · Science & Technology | — | 240,178 | 110,856 | 0 | 0 | 351,034 |
| Alan G. SpoonIndependent · Compensation | — | 240,178 | 110,856 | 0 | 0 | 351,034 |
| Feroz DewanIndependent · Compensation · Nominating & Governance · Science & Technology | — | 240,178 | 110,856 | 0 | 0 | 351,034 |
| John T. SchwietersIndependent · Audit · Nominating & Governance | 130,000 | 110,178 | 110,856 | 0 | 0 | 351,034 |
| Jessica L. Mega, MD, MPHIndependent · Departed during FY | 130,000 | 110,178 | 110,856 | 0 | 0 | 351,034 |
| Rainer M. BlairEmployee director · Executive · Finance · Science & Technology | 0 | 0 | 0 | — | 0 | 0 |
| Mitchell P. RalesEmployee director · Executive (Chair) · Finance (Chair) | 0 | 0 | 0 | — | 0 | 0 |
| Steven M. RalesEmployee director · Board Chair · Executive · Finance · Science & Technology | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | $2,000 |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 25,000 / 25,000 |
| Stock ownership guideline | Once a director has acquired a number of shares that satisfies such ownership multiple, such number of shares then becomes such director’s minimum ownership requirement |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $722,150 |
| Equity awards (grant-date value) | $1,822,972 |
| All other compensation | $0 |
| Total cost of the board | $2,545,122 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Danaher Corp /DE/ as a peer
Companies that benchmark against DHR
28 companies name DHR as a compensation peer
- ABBOTT LABORATORIESABTFY2025
- AGILENT TECHNOLOGIES, INC.AFY2025
- Baker Hughes CoBKRFY2025
- BAXTER INTERNATIONAL INCBAXFY2025
- BECTON DICKINSON & COBDXFY2025
- BOSTON SCIENTIFIC CORPBSXFY2025
- CARDINAL HEALTH INCCAHFY2026
- CORNING INC /NYGLWFY2025
- CVS HEALTH CorpCVSFY2025
- ECOLAB INC.ECLFY2025
- ELI LILLY & CoLLYFY2025
- EMERSON ELECTRIC COEMRFY2025
- GE HealthCare Technologies Inc.GEHCFY2025
- HCA Healthcare, Inc.HCAFY2025
- IQVIA HOLDINGS INC.IQVFY2025
- JABIL INCJBLFY2025
- LINDE PLCLINFY2024
- MARKEL GROUP INC.MKLFY2025
- Medline Inc.MDLNFY2025
- Medtronic plcMDTFY2026
- NUCOR CORPNUEFY2025
- REVVITY, INC.RVTYFY2025
- Solventum CorpSOLVFY2025
- STRYKER CORPSYKFY2025
- THERMO FISHER SCIENTIFIC INC.TMOFY2025
- Trane Technologies plcTTFY2025
Each company listed discloses DHR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DHR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
IQV IQVIA Holdings Inc.ABBV AbbVie Inc.A Agilent TechnologiesAMGN Amgen Inc.BDX Becton Dickinson & Co.BSX Boston Scientific CorporationBMY Bristol-Myers Squibb CompanyLLY Eli Lilly and CompanyGILD Gilead SciencesJNJ Johnson & JohnsonMDT Medtronic Inc.MRK Merck & Co.SYK Stryker CorporationTMO Thermo Fisher Scientific Inc.
Peer reciprocity
Of the companies Danaher Corp /DE/ names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
✓ IQVIA Holdings Inc. (IQV)122— AbbVie Inc. (ABBV)123✓ Agilent Technologies (A)124— Amgen Inc. (AMGN)125✓ Becton Dickinson & Co. (BDX)126✓ Boston Scientific Corporation (BSX)127— Bristol-Myers Squibb Company (BMY)128✓ Eli Lilly and Company (LLY)129— Gilead Sciences (GILD)130— Johnson & Johnson (JNJ)131 Medtronic Inc. (MDT)— Merck & Co. (MRK)132✓ Stryker Corporation (SYK)133 Thermo Fisher Scientific Inc. (TMO)
Reciprocity shown where the peer’s own current proxy has been read — each mark is cited in the register to that peer’s filing. A dash means the peer’s current proxy was read and names no reciprocal group including Danaher Corp /DE/.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific Inc. | 2025 | Marc Casper | $1,785,534 | $65,730,211 | $7,951,377 | $3,742,123 | $79,923,350 |
| 2 | Eli Lilly and Company | 2025 | David Ricks | 1,700,000 | 23,325,000 | 0 | 6,485,500 | 36,698,337 |
| 3 | Johnson & Johnson | 2025 | Joaquin Duato | 1,600,000 | 15,028,948 | 5,927,995 | 4,298,700 | 32,758,111 |
| 4 | AbbVie Inc. | 2025 | Robert Michael | 1,700,000 | 13,268,456 | 3,199,154 | 5,200,000 | 32,530,984 |
| 5 | Gilead Sciences | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 6 | Iqvia Holdings Inc. | 2025 | Ari Bousbib | 1,800,000 | 15,749,957 | 4,528,317 | 4,966,127 | 28,128,245 |
| 7 | Amgen Inc. | 2025 | Robert Bradway | 1,925,409 | 12,599,589 | 5,399,996 | 3,907,000 | 24,693,120 |
| 8 | Danaher Corp /DE/ | 2025 | Rainer Blair | 1,400,000 | 9,292,370 | 8,386,657 | 4,194,400 | 23,795,280 |
| 9 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 10 | Medtronic Inc. | 2026 | Geoffrey Martha | 1,399,039 | 13,672,200 | 5,175,559 | 2,307,200 | 22,940,252 |
| 11 | Bristol-Myers Squibb Company | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 12 | Stryker Corporation | 2025 | Kevin Lobo | 1,500,000 | 9,764,136 | 6,920,781 | 2,250,000 | 21,401,495 |
| 13 | Merck & Co. | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 14 | Becton Dickinson & Co. | 2025 | Thomas Polen | 1,395,463 | 9,991,854 | 3,311,861 | 1,852,010 | 17,129,140 |
| 15 | Agilent Technologies | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Danaher Corp /DE/ | not disclosed | Options 50 · RSU 50 | Yes — Relative TSR | FW Cook |
| AbbVie Inc. | not disclosed | PSU 40 · PRSU 40 · Option 20 | Yes — Relative TSR | Semler Brossy |
| Agilent Technologies | not disclosed | PSU 60 · Option 20 · RSU 20 | No | Semler Brossy |
| Amgen Inc. | 136.0% | PSU 50 · Options 30 · RSU 20 | Yes — relative TSR | Frederic W. Cook & Co., Inc. (FW Cook) |
| Becton Dickinson & Co. | 85% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| Bristol-Myers Squibb Company | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Eli Lilly and Company | 218% | PSU 100 | No | FW Cook |
| Gilead Sciences | 180% | PSU 50 · Option 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Iqvia Holdings Inc. | not disclosed | PSU 75 · Options 25 | Yes | Meridian Compensation Partners, LLC |
| Johnson & Johnson | not disclosed | not disclosed | Yes — Relative TSR | Semler Brossy Consulting Group |
| Medtronic Inc. | 103% | PSU 50 · Options 30 · RSU 20 | No | Semler Brossy |
| Merck & Co. | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| Stryker Corporation | 100% | PSU 48 · Options 34 | No | Semler Brossy |
| Thermo Fisher Scientific Inc. | 99.8% | PSU 50 · Options 50 | Yes — Relative TSR | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-05 | 553,754,519 | 41,555,863 | 473,274 | 93.02% | Passed |
| 2025 | 2025-05-06 | 562,800,461 | 30,795,342 | 2,887,987 | 94.81% | Passed |
| 2024 | 2024-05-07 | 586,649,118 | 41,950,464 | 2,206,701 | 93.33% | Passed |
| 2023 | 2023-05-09 | 587,524,847 | 31,456,091 | 1,576,630 | 94.92% | Passed |
| 2022 | 2022-05-10 | 561,170,146 | 35,745,911 | 959,988 | 94.01% | Passed |
| 2021 | 2021-05-05 | 575,840,385 | 28,142,256 | 1,462,916 | 95.34% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-05 | 93.02%a |
| 2025 | 2025-05-06 | 94.81%b |
| 2024 | 2024-05-07 | 93.33%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 343 : 1 |
|---|---|
| CEO total compensation | $23,795,280 |
| Median employee compensation | $69,440 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dividend-equivalent accruals | 2026-04-24 | — | 37 | — | ~6,624 | 2 insiders, 2 accrual rows | ||
| Raymond C. Stevens | Director | 2026-04-24 | A | 199.26 | 177 | 35,319 | Derivative, Class A Common | Form 4 ↗ |
| Feroz Dewan | Director | 2026-04-24 | A | 187.89 | 177 | 33,304 | Derivative, Class A Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-04-24 | A | 252.32 | 177 | 44,724 | Derivative, Class A Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-04-24 | A | 259.72 | 177 | 46,035 | Derivative, Class A Common | Form 4 ↗ |
| A. Shane Sanders | Director | 2026-04-24 | A | 231.81 | 177 | 41,088 | Derivative, Class A Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-05-01 | D | 1,358 | 175 | 237,207 | Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-05-01 | A | 3,298 | 72 | 237,060 | Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-05-01 | D | 3,298 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Teri L. List | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-15 | — | 13,592 | — | — | 8 insiders, 8 accrual rows | ||
| Charles W. Lamanna | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Raymond C. Stevens | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Georgeann Couchara | SVP, Human Resources | 2026-05-15 | D | 281 | 162 | 45,497 | Common | Form 4 ↗ |
| Linda Filler | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Feroz Dewan | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| A. Shane Sanders | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Linda Filler | Director | 2026-07-15 | D | 1,181 | 201 | 237,133 | Common | Form 4 ↗ |
| Linda Filler | Director | 2026-07-15 | A | 3,298 | 72 | 237,060 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-07-15 | D | 60 | 201 | 12,047 | Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-07-15 | D | 3,298 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-07-15 | A | 3,298 | 72 | 237,060 | Common | Form 4 ↗ |
| Linda Filler | Director | 2026-07-15 | D | 3,298 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-07-15 | D | 1,181 | 201 | 237,133 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-31 | — | 34 | — | ~6,639 | 2 insiders, 2 accrual rows | ||
| Elias A. Zerhouni, MD | Director | 2026-07-31 | A | 236.63 | 195 | 46,139 | Derivative, Class A Common | Form 4 ↗ |
| A. Shane Sanders | Director | 2026-07-31 | A | 211.21 | 195 | 41,181 | Derivative, Class A Common | Form 4 ↗ |
| Raymond C. Stevens | Director | 2026-07-31 | A | 181.55 | 195 | 35,398 | Derivative, Class A Common | Form 4 ↗ |
| Feroz Dewan | Director | 2026-07-31 | A | 171.2 | 195 | 33,380 | Derivative, Class A Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-07-31 | A | 229.9 | 195 | 44,825 | Derivative, Class A Common | Form 4 ↗ |
| Steven M. Rales | Director | 2026-08-04 | A | 1,000,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mitchell P. Rales | Director | 2026-08-04 | A | 1,000,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Leiken | SVP-Chief Legal Officer | 2026-08-04 | A | 92,138 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory M. Milosevich | Executive Vice President | 2026-08-04 | A | 15,402 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Riley | Executive Vice President | 2026-08-04 | A | 41,072 | 0 | 0 | Common | Form 4 ↗ |
| Matthew E. Gugino | EVP & Chief Financial Officer | 2026-08-04 | A | 153,563 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jose-Carlos Gutierrez-Ramos | SVP, Chief Science Officer | 2026-08-04 | A | 13,477 | 0 | 0 | Common | Form 4 ↗ |
| Steven M. Rales | Director | 2026-08-04 | A | 500,000 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-08-04 | A | 12,286 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sawyer Montgomery Julie A | Executive Vice President | 2026-08-04 | A | 245,701 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mitchell P. Rales | Director | 2026-08-04 | A | 500,000 | 0 | 0 | Common | Form 4 ↗ |
| Rainer Blair | Director | 2026-08-21 | D | 7,755 | 219 | 1,701,053 | Common | Form 4 ↗ |
| Rainer Blair | Director | 2026-08-21 | D | 39,193 | 219 | 8,572,704 | Common | Form 4 ↗ |
| Rainer Blair | Director | 2026-08-21 | D | 11,307 | 218 | 2,462,338 | Common | Form 4 ↗ |
| Mitchell P. Rales | Director | 2026-10-09 | D | 500,000 | 0 | 0 | Common | Form 4 ↗ |
| Steven M. Rales | Director | 2026-10-09 | D | 500,000 | 0 | 0 | Common | Form 4 ↗ |
| Matthew McGrew | Executive Vice President | 2026-10-28 | D | 15,603 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew McGrew | Executive Vice President | 2026-10-28 | D | 15,603 | 236 | 3,683,773 | Common | Form 4 ↗ |
| Matthew McGrew | Executive Vice President | 2026-10-28 | A | 15,603 | 76 | 1,193,161 | Common | Form 4 ↗ |
| Matthew McGrew | Executive Vice President | 2026-10-28 | D | 14,151 | 235 | 3,330,470 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | D | 3,253 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | D | 4,345 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | D | 3,253 | 235 | 763,094 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | A | 3,253 | 71 | 230,117 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | D | 4,345 | 235 | 1,019,063 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | A | 4,345 | 71 | 307,365 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 67 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Linda Filler | Director | 2026-04-24 | A | 20.12 | $177 | $3,566 | Derivative, Class A Common | Form 4 ↗ |
| Raymond C. Stevens | Director | 2026-04-24 | A | 199.26 | 177 | 35,319 | Derivative, Class A Common | Form 4 ↗ |
| Teri L. List | Director | 2026-04-24 | A | 17.25 | 177 | 3,057 | Derivative, Class A Common | Form 4 ↗ |
| Feroz Dewan | Director | 2026-04-24 | A | 187.89 | 177 | 33,304 | Derivative, Class A Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-04-24 | A | 252.32 | 177 | 44,724 | Derivative, Class A Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-04-24 | A | 259.72 | 177 | 46,035 | Derivative, Class A Common | Form 4 ↗ |
| A. Shane Sanders | Director | 2026-04-24 | A | 231.81 | 177 | 41,088 | Derivative, Class A Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-05-01 | D | 1,358 | 175 | 237,207 | Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-05-01 | A | 3,298 | 72 | 237,060 | Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-05-01 | D | 3,298 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Teri L. List | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Charles W. Lamanna | Director | 2026-05-15 | A | 1,699 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Lamanna | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Feroz Dewan | Director | 2026-05-15 | A | 1,699 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-05-15 | A | 1,699 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Teri L. List | Director | 2026-05-15 | A | 1,699 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Raymond C. Stevens | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Georgeann Couchara | SVP, Human Resources | 2026-05-15 | D | 281 | 162 | 45,497 | Common | Form 4 ↗ |
| Linda Filler | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Feroz Dewan | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| A. Shane Sanders | Director | 2026-05-15 | A | 1,699 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-05-15 | A | 1,699 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Raymond C. Stevens | Director | 2026-05-15 | A | 1,699 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| A. Shane Sanders | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-05-15 | A | 680 | 0 | 0 | Common | Form 4 ↗ |
| Linda Filler | Director | 2026-05-15 | A | 1,699 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Linda Filler | Director | 2026-07-15 | D | 1,181 | 201 | 237,133 | Common | Form 4 ↗ |
| Linda Filler | Director | 2026-07-15 | A | 3,298 | 72 | 237,060 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-07-15 | D | 60 | 201 | 12,047 | Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-07-15 | D | 3,298 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-07-15 | A | 3,298 | 72 | 237,060 | Common | Form 4 ↗ |
| Linda Filler | Director | 2026-07-15 | D | 3,298 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-07-15 | D | 1,181 | 201 | 237,133 | Common | Form 4 ↗ |
| Teri L. List | Director | 2026-07-31 | A | 15.72 | 195 | 3,064 | Derivative, Class A Common | Form 4 ↗ |
| Elias A. Zerhouni, MD | Director | 2026-07-31 | A | 236.63 | 195 | 46,139 | Derivative, Class A Common | Form 4 ↗ |
| A. Shane Sanders | Director | 2026-07-31 | A | 211.21 | 195 | 41,181 | Derivative, Class A Common | Form 4 ↗ |
| Linda Filler | Director | 2026-07-31 | A | 18.33 | 195 | 3,575 | Derivative, Class A Common | Form 4 ↗ |
| Raymond C. Stevens | Director | 2026-07-31 | A | 181.55 | 195 | 35,398 | Derivative, Class A Common | Form 4 ↗ |
| Feroz Dewan | Director | 2026-07-31 | A | 171.2 | 195 | 33,380 | Derivative, Class A Common | Form 4 ↗ |
| Alan G. Spoon | Director | 2026-07-31 | A | 229.9 | 195 | 44,825 | Derivative, Class A Common | Form 4 ↗ |
| Steven M. Rales | Director | 2026-08-04 | A | 1,000,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mitchell P. Rales | Director | 2026-08-04 | A | 1,000,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Leiken | SVP-Chief Legal Officer | 2026-08-04 | A | 92,138 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory M. Milosevich | Executive Vice President | 2026-08-04 | A | 15,402 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Riley | Executive Vice President | 2026-08-04 | A | 41,072 | 0 | 0 | Common | Form 4 ↗ |
| Matthew E. Gugino | EVP & Chief Financial Officer | 2026-08-04 | A | 153,563 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jose-Carlos Gutierrez-Ramos | SVP, Chief Science Officer | 2026-08-04 | A | 13,477 | 0 | 0 | Common | Form 4 ↗ |
| Steven M. Rales | Director | 2026-08-04 | A | 500,000 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-08-04 | A | 12,286 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sawyer Montgomery Julie A | Executive Vice President | 2026-08-04 | A | 245,701 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mitchell P. Rales | Director | 2026-08-04 | A | 500,000 | 0 | 0 | Common | Form 4 ↗ |
| Rainer Blair | Director | 2026-08-21 | D | 7,755 | 219 | 1,701,053 | Common | Form 4 ↗ |
| Rainer Blair | Director | 2026-08-21 | D | 39,193 | 219 | 8,572,704 | Common | Form 4 ↗ |
| Rainer Blair | Director | 2026-08-21 | D | 11,307 | 218 | 2,462,338 | Common | Form 4 ↗ |
| Mitchell P. Rales | Director | 2026-10-09 | D | 500,000 | 0 | 0 | Common | Form 4 ↗ |
| Steven M. Rales | Director | 2026-10-09 | D | 500,000 | 0 | 0 | Common | Form 4 ↗ |
| Matthew McGrew | Executive Vice President | 2026-10-28 | D | 15,603 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew McGrew | Executive Vice President | 2026-10-28 | D | 15,603 | 236 | 3,683,773 | Common | Form 4 ↗ |
| Matthew McGrew | Executive Vice President | 2026-10-28 | A | 15,603 | 76 | 1,193,161 | Common | Form 4 ↗ |
| Matthew McGrew | Executive Vice President | 2026-10-28 | D | 14,151 | 235 | 3,330,470 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | D | 3,253 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | D | 4,345 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | D | 3,253 | 235 | 763,094 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | A | 3,253 | 71 | 230,117 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | D | 4,345 | 235 | 1,019,063 | Common | Form 4 ↗ |
| Christopher Bouda | VP, Chief Accounting Officer | 2026-10-28 | A | 4,345 | 71 | 307,365 | Common | Form 4 ↗ |
Sources (133 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Rainer Blair. DEF 14A, filed 2026-03-25. Section “2025 Summary Compensation Table” · page 52. As printed: 23,795,280. View filing ↗
- Section 01, Julie Montgomery. DEF 14A, filed 2026-03-25. Section “2025 Summary Compensation Table” · page 52. As printed: 11,295,279. View filing ↗
- Section 01, Christopher Riley. DEF 14A, filed 2026-03-25. Section “2025 Summary Compensation Table” · page 52. As printed: 11,255,848. View filing ↗
- Section 01, Matthew McGrew. DEF 14A, filed 2026-03-25. Section “2025 Summary Compensation Table” · page 52. As printed: 7,967,519. View filing ↗
- Section 01, Jose-Carlos Gutierrez-Ramos. DEF 14A, filed 2026-03-25. Section “2025 Summary Compensation Table” · page 52. As printed: 6,243,771. View filing ↗
- Section 03, Rainer Blair PSU. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jose-Carlos Gutierrez-Ramos PSU. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Riley PSU. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew McGrew OPTION. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew McGrew PSU. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jose-Carlos Gutierrez-Ramos OPTION. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Julie Montgomery OPTION. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Riley OPTION. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Julie Montgomery OPTION. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Riley OPTION. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Rainer Blair OPTION. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Riley PSU. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Julie Montgomery PSU. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Julie Montgomery PSU. DEF 14A, filed 2026-03-25. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-25. Section “CEO Pay Ratio”. As printed: 343 : 1. View filing ↗
- Section 08, Linda Filler. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 413,534. View filing ↗
- Section 08, Teri L. List. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 379,534. View filing ↗
- Section 08, A. Shane Sanders. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 378,534. View filing ↗
- Section 08, Charles W. Lamanna. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 374,684. View filing ↗
- Section 08, Elias A. Zerhouni, MD. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 373,534. View filing ↗
- Section 08, Raymond C. Stevens, Ph.D. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 351,034. View filing ↗
- Section 08, Alan G. Spoon. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 351,034. View filing ↗
- Section 08, Feroz Dewan. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 351,034. View filing ↗
- Section 08, John T. Schwieters. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 351,034. View filing ↗
- Section 08, Jessica L. Mega, MD, MPH. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 351,034. View filing ↗
- Section 08, Rainer M. Blair. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Mitchell P. Rales. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Steven M. Rales. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Linda Filler 2026-04-24. Form 4, filed 2026-04-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raymond C. Stevens 2026-04-24. Form 4, filed 2026-04-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Teri L. List 2026-04-24. Form 4, filed 2026-04-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Feroz Dewan 2026-04-24. Form 4, filed 2026-04-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alan G. Spoon 2026-04-24. Form 4, filed 2026-04-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elias A. Zerhouni, MD 2026-04-24. Form 4, filed 2026-04-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, A. Shane Sanders 2026-04-24. Form 4, filed 2026-04-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alan G. Spoon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alan G. Spoon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alan G. Spoon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Teri L. List 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Lamanna 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Lamanna 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Feroz Dewan 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elias A. Zerhouni, MD 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Teri L. List 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raymond C. Stevens 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Georgeann Couchara 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Linda Filler 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Feroz Dewan 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, A. Shane Sanders 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alan G. Spoon 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elias A. Zerhouni, MD 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raymond C. Stevens 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, A. Shane Sanders 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alan G. Spoon 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Linda Filler 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Linda Filler 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Linda Filler 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Bouda 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elias A. Zerhouni, MD 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elias A. Zerhouni, MD 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Linda Filler 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elias A. Zerhouni, MD 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Teri L. List 2026-07-31. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elias A. Zerhouni, MD 2026-07-31. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, A. Shane Sanders 2026-07-31. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Linda Filler 2026-07-31. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Raymond C. Stevens 2026-07-31. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Feroz Dewan 2026-07-31. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alan G. Spoon 2026-07-31. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven M. Rales 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mitchell P. Rales 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Leiken 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory M. Milosevich 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Riley 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew E. Gugino 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jose-Carlos Gutierrez-Ramos 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven M. Rales 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Bouda 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sawyer Montgomery Julie A 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mitchell P. Rales 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rainer Blair 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rainer Blair 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rainer Blair 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mitchell P. Rales 2026-10-09. Form 4, filed 2026-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven M. Rales 2026-10-09. Form 4, filed 2026-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew McGrew 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew McGrew 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew McGrew 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew McGrew 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Bouda 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Bouda 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Bouda 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Bouda 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Bouda 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Bouda 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-07. Item 5.07 · say-on-pay result. As reported: 93.02% (votes for as printed: 553,754,519). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-08. Item 5.07 · say-on-pay result. As reported: 94.81% (votes for as printed: 562,800,461). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-09. Item 5.07 · say-on-pay result. As reported: 93.33% (votes for as printed: 586,649,118). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 722,150 + equity 1,822,972 + all other 0 = 2,545,122, summed across the director compensation table rows.
- Thermo Fisher Scientific Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Thermo Fisher Scientific Inc.'s own proxy. As printed: 79,923,350. View filing ↗
- Eli Lilly and Company, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. View filing ↗
- Johnson & Johnson, Section 10b CEO total. DEF 14A, filed 2026-03-11. CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. View filing ↗
- AbbVie Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. View filing ↗
- Gilead Sciences, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Gilead Sciences's own proxy. As printed: 28,437,198. View filing ↗
- Iqvia Holdings Inc., Section 10b CEO total. DEF 14A, filed 2026-02-27. CEO total compensation as printed in Iqvia Holdings Inc.'s own proxy. As printed: 28,128,245. View filing ↗
- Amgen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. View filing ↗
- Danaher Corp /DE/ (subject), Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Danaher Corp /DE/'s own proxy. As printed: 23,795,280. View filing ↗
- Boston Scientific Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-18. CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. View filing ↗
- Medtronic Inc., Section 10b CEO total. DEF 14A, filed 2026-08-17. CEO total compensation as printed in Medtronic Inc.'s own proxy. As printed: 22,940,252. View filing ↗
- Bristol-Myers Squibb Company, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. View filing ↗
- Stryker Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. View filing ↗
- Merck & Co., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Merck & Co.'s own proxy. As printed: 20,797,845. View filing ↗
- Becton Dickinson & Co., Section 10b CEO total. DEF 14A, filed 2025-12-18. CEO total compensation as printed in Becton Dickinson & Co.'s own proxy. As printed: 17,129,140. View filing ↗
- Agilent Technologies, Section 10b CEO total. DEF 14A, filed 2026-02-06. CEO total compensation as printed in Agilent Technologies's own proxy. As printed: 12,827,236. View filing ↗
- Section 10a, IQVIA Holdings Inc. reciprocity. DEF 14A. IQVIA Holdings Inc. names Danaher Corp /DE/ in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, AbbVie Inc. reciprocity. DEF 14A. AbbVie Inc.'s most recent proxy was read; its disclosed peer group does not include Danaher Corp /DE/. View filing ↗
- Section 10a, Agilent Technologies reciprocity. DEF 14A. Agilent Technologies names Danaher Corp /DE/ in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Amgen Inc. reciprocity. DEF 14A. Amgen Inc.'s most recent proxy was read; its disclosed peer group does not include Danaher Corp /DE/. View filing ↗
- Section 10a, Becton Dickinson & Co. reciprocity. DEF 14A. Becton Dickinson & Co. names Danaher Corp /DE/ in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Boston Scientific Corporation reciprocity. DEF 14A. Boston Scientific Corporation names Danaher Corp /DE/ in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Bristol-Myers Squibb Company reciprocity. DEF 14A. Bristol-Myers Squibb Company's most recent proxy was read; its disclosed peer group does not include Danaher Corp /DE/. View filing ↗
- Section 10a, Eli Lilly and Company reciprocity. DEF 14A. Eli Lilly and Company names Danaher Corp /DE/ in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Gilead Sciences reciprocity. DEF 14A. Gilead Sciences's most recent proxy was read; its disclosed peer group does not include Danaher Corp /DE/. View filing ↗
- Section 10a, Johnson & Johnson reciprocity. DEF 14A. Johnson & Johnson's most recent proxy was read; its disclosed peer group does not include Danaher Corp /DE/. View filing ↗
- Section 10a, Merck & Co. reciprocity. DEF 14A. Merck & Co.'s most recent proxy was read; its disclosed peer group does not include Danaher Corp /DE/. View filing ↗
- Section 10a, Stryker Corporation reciprocity. DEF 14A. Stryker Corporation names Danaher Corp /DE/ in its own disclosed peer group (read from its most recent proxy). View filing ↗